 Nina Paleologos
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 36 | 2020 | 178 | 3.200 |
Why?
| | Oligodendroglioma | 15 | 2017 | 20 | 1.520 |
Why?
| | Glioblastoma | 10 | 2020 | 22 | 1.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2020 | 378 | 0.710 |
Why?
| | Neoplasm Recurrence, Local | 11 | 2020 | 244 | 0.680 |
Why?
| | Dacarbazine | 6 | 2017 | 11 | 0.460 |
Why?
| | Angiogenesis Inhibitors | 5 | 2013 | 23 | 0.440 |
Why?
| | Antibodies, Monoclonal | 6 | 2011 | 293 | 0.430 |
Why?
| | Antineoplastic Agents, Alkylating | 4 | 2017 | 9 | 0.420 |
Why?
| | Antineoplastic Agents | 6 | 2017 | 244 | 0.410 |
Why?
| | Drug Therapy | 2 | 2009 | 17 | 0.370 |
Why?
| | Evidence-Based Medicine | 8 | 2009 | 235 | 0.350 |
Why?
| | Practice Guidelines as Topic | 6 | 2009 | 388 | 0.340 |
Why?
| | Glioma | 2 | 2005 | 53 | 0.310 |
Why?
| | Astrocytoma | 4 | 2008 | 34 | 0.310 |
Why?
| | Chromosomes, Human, Pair 1 | 4 | 2014 | 15 | 0.280 |
Why?
| | Combined Modality Therapy | 12 | 2011 | 449 | 0.280 |
Why?
| | Radiotherapy, Adjuvant | 5 | 2009 | 81 | 0.260 |
Why?
| | Survival Rate | 13 | 2014 | 443 | 0.260 |
Why?
| | Salvage Therapy | 4 | 2010 | 48 | 0.250 |
Why?
| | Adult | 25 | 2020 | 9848 | 0.230 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2013 | 132 | 0.220 |
Why?
| | Central Nervous System Neoplasms | 2 | 2017 | 21 | 0.220 |
Why?
| | Humans | 41 | 2020 | 32988 | 0.220 |
Why?
| | Radiotherapy | 4 | 2016 | 62 | 0.220 |
Why?
| | Encephalitis, California | 1 | 2000 | 1 | 0.200 |
Why?
| | La Crosse virus | 1 | 2000 | 1 | 0.200 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2000 | 2 | 0.200 |
Why?
| | Middle Aged | 24 | 2017 | 11219 | 0.200 |
Why?
| | Carmustine | 3 | 2017 | 8 | 0.190 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2006 | 128 | 0.190 |
Why?
| | Treatment Outcome | 15 | 2016 | 4036 | 0.180 |
Why?
| | Male | 25 | 2017 | 17726 | 0.170 |
Why?
| | Decanoic Acids | 1 | 2017 | 1 | 0.160 |
Why?
| | Polyesters | 1 | 2017 | 7 | 0.160 |
Why?
| | Female | 25 | 2017 | 18423 | 0.160 |
Why?
| | Disease-Free Survival | 6 | 2017 | 228 | 0.150 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 72 | 0.150 |
Why?
| | Aged | 17 | 2017 | 10542 | 0.140 |
Why?
| | Lomustine | 6 | 2011 | 8 | 0.140 |
Why?
| | Procarbazine | 6 | 2011 | 9 | 0.140 |
Why?
| | Vincristine | 6 | 2011 | 38 | 0.140 |
Why?
| | Cancer Vaccines | 1 | 2015 | 16 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 7 | 2011 | 1315 | 0.130 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2013 | 115 | 0.130 |
Why?
| | Chromosome Deletion | 1 | 2014 | 30 | 0.130 |
Why?
| | Decision Trees | 1 | 2014 | 18 | 0.130 |
Why?
| | Follow-Up Studies | 7 | 2017 | 2053 | 0.130 |
Why?
| | Young Adult | 7 | 2016 | 2287 | 0.120 |
Why?
| | Meningeal Neoplasms | 2 | 2008 | 15 | 0.120 |
Why?
| | Tissue Plasminogen Activator | 1 | 2013 | 78 | 0.120 |
Why?
| | Thiotepa | 4 | 2008 | 5 | 0.110 |
Why?
| | Fibrinolytic Agents | 1 | 2013 | 96 | 0.110 |
Why?
| | Radiosurgery | 2 | 2009 | 42 | 0.110 |
Why?
| | Prognosis | 6 | 2016 | 1011 | 0.110 |
Why?
| | Brain Ischemia | 1 | 2013 | 125 | 0.110 |
Why?
| | Adolescent | 7 | 2014 | 2687 | 0.100 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 20 | 0.090 |
Why?
| | Blood-Brain Barrier | 1 | 1990 | 45 | 0.090 |
Why?
| | Adrenal Cortex Hormones | 1 | 2010 | 113 | 0.090 |
Why?
| | Steroids | 1 | 2009 | 31 | 0.090 |
Why?
| | Guidelines as Topic | 1 | 2009 | 78 | 0.090 |
Why?
| | Survival Analysis | 4 | 2008 | 372 | 0.090 |
Why?
| | Seizures | 1 | 2009 | 93 | 0.090 |
Why?
| | Neurosurgery | 1 | 2009 | 48 | 0.090 |
Why?
| | Stroke | 1 | 2013 | 405 | 0.090 |
Why?
| | Meninges | 1 | 2008 | 8 | 0.080 |
Why?
| | Movement Disorders | 1 | 1990 | 149 | 0.080 |
Why?
| | Anticoagulants | 1 | 2009 | 153 | 0.080 |
Why?
| | Disease Progression | 5 | 2011 | 870 | 0.080 |
Why?
| | Meningioma | 1 | 2008 | 19 | 0.080 |
Why?
| | Molecular Biology | 1 | 2007 | 14 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2014 | 3835 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 216 | 0.070 |
Why?
| | Expert Testimony | 1 | 2005 | 17 | 0.070 |
Why?
| | Prospective Studies | 5 | 2017 | 2002 | 0.070 |
Why?
| | Cranial Irradiation | 3 | 2009 | 17 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2015 | 5249 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2011 | 1061 | 0.060 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2003 | 55 | 0.060 |
Why?
| | DNA Modification Methylases | 2 | 2016 | 7 | 0.060 |
Why?
| | Cognition | 1 | 2011 | 1325 | 0.060 |
Why?
| | International Agencies | 2 | 2012 | 5 | 0.050 |
Why?
| | Transplantation, Autologous | 2 | 2017 | 221 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2014 | 457 | 0.050 |
Why?
| | DNA Methylation | 2 | 2016 | 169 | 0.050 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2012 | 4 | 0.050 |
Why?
| | Serologic Tests | 1 | 2000 | 15 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2020 | 49 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2010 | 71 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2000 | 54 | 0.050 |
Why?
| | Parkinson Disease | 1 | 1990 | 1259 | 0.050 |
Why?
| | Iodine Radioisotopes | 2 | 1998 | 23 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2000 | 462 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 1999 | 78 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1999 | 90 | 0.040 |
Why?
| | Tenascin | 1 | 1998 | 3 | 0.040 |
Why?
| | Karnofsky Performance Status | 3 | 2008 | 7 | 0.040 |
Why?
| | Alleles | 1 | 1999 | 231 | 0.040 |
Why?
| | Drug Implants | 1 | 2017 | 14 | 0.040 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2017 | 4 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 1999 | 101 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2009 | 377 | 0.040 |
Why?
| | Databases, Factual | 2 | 2009 | 393 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 52 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 1999 | 368 | 0.040 |
Why?
| | Radioimmunotherapy | 1 | 1996 | 5 | 0.040 |
Why?
| | Registries | 1 | 2017 | 226 | 0.040 |
Why?
| | Radiotherapy Dosage | 2 | 2012 | 147 | 0.040 |
Why?
| | Brain | 3 | 2008 | 1752 | 0.040 |
Why?
| | Research Design | 1 | 2017 | 244 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 1999 | 899 | 0.030 |
Why?
| | Vaccines, Subunit | 1 | 2015 | 3 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2015 | 20 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2015 | 79 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 87 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2013 | 289 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 2013 | 84 | 0.030 |
Why?
| | Gene Deletion | 1 | 2012 | 54 | 0.030 |
Why?
| | Etoposide | 2 | 2003 | 64 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2010 | 101 | 0.020 |
Why?
| | Biological Transport | 1 | 1990 | 48 | 0.020 |
Why?
| | United States | 1 | 2017 | 2632 | 0.020 |
Why?
| | Metalloporphyrins | 1 | 2009 | 3 | 0.020 |
Why?
| | MEDLINE | 1 | 2009 | 7 | 0.020 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2009 | 12 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 45 | 0.020 |
Why?
| | Camptothecin | 1 | 2009 | 6 | 0.020 |
Why?
| | Algorithms | 1 | 2012 | 428 | 0.020 |
Why?
| | DNA Repair Enzymes | 1 | 2008 | 10 | 0.020 |
Why?
| | Loss of Heterozygosity | 1 | 2008 | 6 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 249 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2008 | 38 | 0.020 |
Why?
| | Busulfan | 1 | 2008 | 5 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 111 | 0.020 |
Why?
| | Cerebellopontine Angle | 1 | 2008 | 6 | 0.020 |
Why?
| | Cerebrum | 1 | 2008 | 6 | 0.020 |
Why?
| | Time | 1 | 2008 | 21 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2008 | 92 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2008 | 232 | 0.020 |
Why?
| | Data Collection | 1 | 2007 | 118 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2011 | 1306 | 0.020 |
Why?
| | Neurosurgical Procedures | 1 | 2008 | 168 | 0.020 |
Why?
| | Cohort Studies | 1 | 2011 | 2077 | 0.020 |
Why?
| | Cytarabine | 1 | 2003 | 13 | 0.020 |
Why?
| | Melphalan | 1 | 2003 | 18 | 0.020 |
Why?
| | Safety | 1 | 2003 | 55 | 0.020 |
Why?
| | Remission Induction | 1 | 2003 | 111 | 0.020 |
Why?
| | Methotrexate | 1 | 2003 | 47 | 0.010 |
Why?
| | Bone Marrow Diseases | 1 | 2000 | 9 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2000 | 41 | 0.010 |
Why?
| | Cachexia | 1 | 2000 | 15 | 0.010 |
Why?
| | Cisplatin | 1 | 2000 | 106 | 0.010 |
Why?
| | Treatment Failure | 1 | 2000 | 186 | 0.010 |
Why?
| | Brain Diseases | 1 | 2000 | 88 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1998 | 13 | 0.010 |
Why?
| | Injections, Intralesional | 1 | 1998 | 34 | 0.010 |
Why?
| | Cerebral Hemorrhage | 1 | 2000 | 151 | 0.010 |
Why?
| | Immunoassay | 1 | 1998 | 47 | 0.010 |
Why?
| | Immunotherapy | 1 | 1998 | 75 | 0.010 |
Why?
| | Biopsy | 1 | 1998 | 277 | 0.010 |
Why?
| | Mitomycin | 1 | 1996 | 13 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1998 | 159 | 0.010 |
Why?
| | Quality Assurance, Health Care | 1 | 1996 | 56 | 0.010 |
Why?
| | Child, Preschool | 1 | 1996 | 798 | 0.010 |
Why?
| | Child | 1 | 1998 | 1634 | 0.010 |
Why?
| | Mice | 1 | 1996 | 1958 | 0.010 |
Why?
| | Animals | 1 | 1996 | 5371 | 0.000 |
Why?
| | Time Factors | 1 | 1990 | 1873 | 0.000 |
Why?
|
|
Paleologos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|